Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Sepracor to develop (S)-doxazosin for BPH; U.S. patent granted

Aug. 16, 1996

Leiras claims oral delivery system for oxybutynin chloride

July 26, 1996

Novo Nordisk claims xanomeline as potential urinary bladder disorder treatment

July 26, 1996

Positive results in trial of Cystistat in refractory interstitial cystitis patients

July 19, 1996

CGP-53153: Ciba-Geigy's steroidal 5alpha-reductase inhibitor as BPH therapy

July 19, 1996

Glaxo Wellcome describes alpha1A-adrenoceptor antagonists

July 19, 1996

Cystistat covered under U.S. patent

July 12, 1996

5alpha-Reductase inhibitors from Kyowa Hakko

July 12, 1996

Selective alpha1A-adrenoceptor antagonists with multiple indications

July 12, 1996

Flutamide BPH trial results reported

July 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...